GlassScriptPhysician profile
William Ray Stroud
NPI 1144580861
$2,180.24
in general payments reported to CMS, 2019-2025
29 companies · $356 in 2025
The $356 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $383 · 2020: $258 · 2021: $532 · 2022: $504 · 2023: $20.80 · 2024: $127 · 2025: $356.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $504.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $503.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $326.30 | 2019-2022 | |
| Mayne Pharma Commercial LLC | $242.99 | 2021-2025 | |
| Hologic Sales and Service, LLC | $218.65 | 2019-2024 | Fluent Fluid Management System, Myosure Tissue Removal Device |
| Pfizer INC. | $190.01 | 2019-2023 | |
| Therapeuticsmd, INC. | $145.28 | 2019-2022 | |
| Daiichi Sankyo INC. | $124.94 | 2019-2021 | |
| Exeltis, USA INC. | $113.75 | 2020-2025 | Slynd |
| Minerva Surgical, INC | $98.61 | 2020-2025 | |
| Channel Medsystems, INC. | $94.89 | 2022 | |
| Sumitomo Pharma America, INC. | $66.80 | 2024-2025 | Gemtesa |
| Bayer Healthcare Pharmaceuticals INC. | $64.86 | 2021-2022 | |
| Novo Nordisk INC | $50.77 | 2025 | Wegovy |
| Organon LLC | $39.12 | 2022-2024 | |
| Myovant Sciences INC. | $37.94 | 2021 | |
| Scynexis, INC. | $36.21 | 2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $35.96 | 2024-2025 | Veozah |
| Aspira Women'S Health INC | $35.53 | 2021 | |
| Shield Therapeutics INC | $32.90 | 2024 | |
| Merck Sharp & Dohme LLC | $28.06 | 2019-2021 | |
| Mylan Pharmaceuticals INC. | $26.06 | 2019-2022 | |
| Avion Pharmaceuticals | $24.56 | 2020-2021 | |
| Amag Pharmaceuticals, INC. | $24.40 | 2019 | |
| Lupin INC. | $23.90 | 2019-2020 | |
| Sage Therapeutics, LLC | $20.74 | 2025 | Zurzuvae |
| Lilly USA, LLC | $20.14 | 2025 | Zepbound |
| Agile Therapeutics, INC. | $16.92 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.00 | 2021 | |
| Merz North America, INC. | $12.98 | 2022 | |
| Evofem Biosciences, INC. | $11.97 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Stroud listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.